Inhibitors of type 2 sodium glucose co-transporters - A new strategy for diabetes treatment

Pharmacological Reports

Volumn 61, Issue 5, 2009, Pages 778-784

  Bołdys, Aleksandra ^a   Okopień, Bogusław ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Diabetes; SGLT2 inhibitor; Sodium glucose co transporters

Indexed keywords

ACARBOSE; ANTIDIABETIC AGENT; AVE 2268; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLITAZONE DERIVATIVE; INSULIN; ISIS 388626; JNJ 28431754; METFORMIN; PLACEBO; PROTEIN INHIBITOR; REMOGLIFLOZIN; REMOGLIFLOZIN ETABONATE; SERGLIFLOZIN; SERGLIFLOZIN ETABONATE; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; UNCLASSIFIED DRUG;

BINDING AFFINITY; CLINICAL TRIAL; DOWN REGULATION; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; GLUCOSE URINE LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; HYPOTENSION; KIDNEY TUBULE ABSORPTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; WEIGHT REDUCTION;

EID: 70549104946     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(09)70133-1     Document Type: Review

References (35)

1. American Diabetes Association: Standards of medical care in diabetes 2008. Diabetes Care, 2008, 31, Suppl 1, S12-S54
2. Bell DS: Type 2 diabetes mellitus: what is the optimal treatment regimen? Am J Med, 2004, 116, 23S-29S.
3. Calado J, Loeffler J, Sakalliouglu O, Gok F, Lhotta K, Barata J, Rueff J: Familial renal glucosuria: SGLC5A2 mutation analysis and evidence of salt-wasting. Kidney Int, 2006, 69, 852-855. (Pubitemid 43297895)
4. Dluhy RG, McMahon GT: Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med, 2008, 358, 2630-2633.
5. Ehrenkranz JRL, Lewis NG, Kahn CR, Roth J: Phlorizin: a review. Diabetes Metab Res Rev, 2005, 21, 31-38.
6. Fujimori Y, Katsuno K, Nakashima I, Ishikawa-Takemura Y, Fujikura H, Isaji M: Remogliflozin etabonate, in a novel category of selective low-affinity/high-capacity sodium glucose cotransporter (SGLT-2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther, 2008, 327, 268-276.
7. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med, 2003, 348, 383-393. (Pubitemid 36159355)
8. Geerlings SE, Stolk RP, Camps MJ, Netten PM, Collet TJ, Hoepelman AI; Diabetes Women Asymptomatic Bacteriuria Utrecht Study Group: Risk factors for symptomatic urinary tract infections in women with diabetes. Diabetes Care, 2000, 23, 1737-1741.
9. Grigoriou O, Baka S, Makrakis E, Hassiakos D, Kapparos E: Prevalence of clinical vaginal candidiasis in a university hospital and possible risk factors. Eur J Obstet Gynecol Reprod Biol, 2006, 126, 121-125.
10. Han S, Hagan DL, Taylor JR, Xin L, Meng W, Biller SA, Wetterau Jr et al.: Dapagliflozin, a selective SGLT-2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes, 2008, 57, 1723-1729.
11. Handlon AL: Sodium glucose co-transporter 2 (SGLT-2) inhibitors as potential antidiabetic agents. Expert Opin Ther Pat, 2005, 15, 1531-1540. (Pubitemid 41671615)
12. Isaji M: Sodium-glucose cotransporter inhibitors for diabetes. Curr Opin Investig Drugs, 2007, 8, 285-292.
13. Jabbour SA, Goldstein BJ: Sodium-glucose cotransporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. Int J Clin Pract, 2008, 62, 1279-1284.
14. Johnson & Johnson Pharmaceutical Research & Development, L.L.C.: A randomized, double-blind, placebo-controlled, double-dummy, parallel group, multicenter, dose-ranging study in subjects with type 2 diabetes mellitus to evaluate the efficacy, safety, and tolerability of orally administered SGLT2 inhibitor JNJ-28431754 with sitagliptin as a reference arm. NCT00642278.
15. Kahn BB, Shulman GI, DeFronzo RA, Cushman SW, Rossetti L: Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin-resistant glucose transport in adipose cells without restoring glucose transporter gene expression. J Clin Invest, 1991, 87, 561-570.
16. +/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest, 1994, 93, 397-404. (Pubitemid 24983192)
17. Katsuno K, Fujimori Y, Takemura Y, Hiratochi M, Itoh F, Komatsu Y, Fujikura H, Isaji M: Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther, 2007, 320, 323-330. (Pubitemid 46025747)
18. L'Abbate A: Large and micro coronary vascular involvement in diabetes. Pharmacol Rep, 2005, 57, Suppl, 3-9.
19. +/glucose cotransporters in renal proximal tubule cells. Kidney Int Suppl, 2007, 106, S27-S35.
20. List JF, Woo V, Morales E, Tang W, Fiedorek FT: Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes mellitus. Diabetes Care, 2009, 32, 650-657.
21. Madej A, Okopień B, Kowalski J, Haberka M, Herman ZS: Plasma concentrations of adhesion molecules and chemokines in patients with essential hypertension. Pharmacol Rep, 2005, 57, 878-881
22. Malatiali S, Francis I, Barac-Nieto F: Phlorizin prevents glomerular hyperfiltration but not hypertrophy in diabetic rats. Exp Diabetes Res, 2008, 305403.
23. Nathan DM, Burse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B: Management of hyperglycaemia in type 2 diabetes: A consensus alghoritm for the initiation and adjustment of therapy. A consensus statement for the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia, 2006, 49, 1711-1721.
24. Okopien B, Huzarska M, Kulach A, Stachura-Kulach A, Madej A, Belowski D, Zielinski M, Herman ZS: Hypolipidemic drugs affect monocyte IL-1β gene expression and release in patients with IIa and IIb dyslipidemia. J Cardiovasc Pharmacol, 2005, 45, 160-164. (Pubitemid 40170679)
25. +/glucose cotransporters. J Pharmacol Exp Ther, 2008, 324, 985-991.
26. Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J: Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes, 2005, 54, 3427-3434. (Pubitemid 43334332)
27. Santer R, Kinner M, Lassen CL, Schneppenheim R, Eggert P, Bald M, Brodehl J et al.: Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol. 2003, 14, 2873-2882.
28. Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, Hadden D et al.: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ, 2000, 321, 405-412.
29. Tanabe Seiyaku Co. Ltd.: Annual Report 2008. Mitsubishi Chemical Holdings Corporation, 2008, 28.
30. Vallon V, Richter K, Blantz RC, Thomson S, Osswald H: Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. J Am Soc Nephrol, 1999, 10, 2569-2576.
31. Van den Heuvel LP, Assink K, Willemsen M, Monnens L: Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2). Hum Genet, 2002, 111, 544-547.
32. Wild S, Roglic G, Green A, Sicree R, King H: Global Prevalence of Diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care, 2004, 27, 1047-1053.
33. World Health Organization: International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 59. WHO Drug Information, 2008, 22, 50.
34. World Health Organization: International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 59. WHO Drug Information, 2008, 22, 66.
35. Wright EM, Hirayama BA, Loo DF: Active sugar transport in health and disease. J Intern Med, 2007, 261, 32-43.